3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Temozolomide
24
Radiotherapy
10
Magnetic Resonance Spectroscopy
10
Radiation
8
Specimen Handling
7
Lomustine
5
Bevacizumab
4
Nivolumab
3
Biopsy
3
Aminolevulinic Acid
3
veliparib
2
trametinib
2
olaparib
2
lutetium Lu 177 dotatate
2
dabrafenib
2
cemiplimab
2
azeliragon
2
Surgical Procedures, Operative
2
Receptors, Interleukin-8B
2
Photons
2
Palliative Care
2
Ipilimumab
2
D2C7-(scdsFv)-PE38KDEL
2
Carboplatin
2
CTLA-4 Antigen
2
vocimagene amiretrorepvec
1
varlilumab
1
ulixertinib
1
tinostamustine
1
temsirolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Glioblastoma
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.